 Omeros Corporation NASDAQ: OMER announced long-term follow-up 35 months results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab showed a median reduction in proteinuria of 64.4. 